Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
- Status
- UNKNOWN
- Phase
- PHASE4
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Status
- UNKNOWN
- Phase
- PHASE2
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study
- Status
- COMPLETED
- Phase
- N/A
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
- Status
- COMPLETED
- Phase
- N/A
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
- Status
- COMPLETED
- Phase
- PHASE3
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
- Status
- COMPLETED
- Phase
- PHASE2
Treatment-free Remission Accomplished With Dasatinib in Patients With CML
- Status
- UNKNOWN
- Phase
- PHASE2